Endpoint Health blog · Dec 2024
The company highlighted a podcast interview featuring co-founder and CSO Diego Rey discussing Endpoint Health’s mission to bring lifesaving targeted therapies to critically ill patients.
Precision-first therapies
Company research
Public company, workplace, funding, and market signals
Overview
Endpoint Health is a precision-first biotechnology/therapeutics company focused on immune-driven critical and chronic illness. It combines therapeutics, companion diagnostics, and AI to personalize treatment and develop targeted therapies, especially for sepsis, ARDS, rheumatoid arthritis, and IBD.
Primary product
Precision-first therapeutics platform combining companion diagnostics and AI with targeted therapies for immune-driven diseases.
Founded
2018
Headquarters
Palo Alto, California, United States
Team size
1-10
Industry
Biotechnology Research
Sub-industry
Precision therapeutics / precision medicine
Offices
Palo Alto, California
Livonia, Michigan
Detroit, Michigan
Chicago, Illinois
Business model
therapeutics development
companion diagnostics
AI-enabled clinical decision support
biopharma collaboration and licensing
Funding
Stage
Series A
Total raised
$64.1M
Latest round
Series A · Jun 2022
Latest amount
$52M
People & investors
Leadership
Co-Founder and CEO
Co-Founder and COO
Co-Founder and Chief Scientific Officer
Ransi Somaratne, M.D.
Chief Medical Officer
Jeff Osborn
Co-Founder and Chief Technology Officer
David Leonard
COO & Head of Corporate Development
Kristen Taylor Meadows
Vice President, Discovery & Translational Science
Akbar Khan
Vice President, Clinical Operations
Julie Friedman
Vice President, Therapeutic Operations & Program Management
Pamela H.
Vice President of Finance
Work & culture
Public materials present a mission-driven, science-heavy culture centered on precision medicine, cross-functional collaboration across therapeutics/diagnostics/AI, and partnerships with hospitals and biopharma companies.
Product & market
Pricing
Primarily B2B collaboration/licensing and clinical-development partnership model; public materials do not disclose standard subscription or list pricing.
Differentiators
- —Combines therapeutics, diagnostics, and AI in one platform
- —Focuses on immune-driven critical illness rather than broad one-size-fits-all indications
- —Uses patient subtyping / transcriptomic tests to match therapy to biology
- —Builds targeted therapies through partnerships rather than only de novo drug discovery
- —Backed by precision-medicine and Silicon Valley investors
Technology
WordPress
Cloudflare Rocket Loader
HTTP/3
Yoast SEO
Google Analytics
cookies/pixel tags
LinkedIn social widget
Customers
Hospitals and medical centers
Clinicians treating critically ill patients
Biopharma/pharma partners
Vanderbilt University Medical Center
Grifols
Competitors
Second Genome
Seres Therapeutics
Dicerna Pharmaceuticals
Intellia Therapeutics
Alnylam Pharmaceuticals
Editas Medicine
4D pharma
Corvus Pharmaceuticals
Finch Therapeutics
Allogene Therapeutics
Scale & contact
Estimated revenue
$1M-$10M (public LinkedIn estimate; ~US$5.6M annual revenue shown in profile snippets)
Estimated monthly visits
1.2K
Traffic estimate as of Jun 2026
Latest news
Business Wire · Sep 2022
Endpoint Health named biotech veteran Ransi Somaratne as its first CMO to lead clinical strategy and drug-development programs across its precision-immunology pipeline.
Business Wire · Jun 2022
The company closed $52M in equity and debt financing, with investors including Mayfield, Humboldt Fund, AME Cloud Ventures, Boom Capital, Alix Ventures, Yaya Capital, Wireframe Ventures, The Venture Collective, HCX Ventures, and GHIC.
Business Wire · Feb 2022
Endpoint Health reported retrospective analyses in SHOCK suggesting immune-state gene-expression subtyping may identify septic-shock patients with different corticosteroid response and mortality outcomes.
Business Wire · Feb 2022
Endpoint Health and Grifols agreed to develop and commercialize Antithrombin III for sepsis, with Grifols providing up to $25M to support clinical development and the companies jointly funding manufacturing expansion after FDA approval.
Jobs and careers at Endpoint Health
0 jobs at Endpoint Health
No open positions
Check back later for new openings